Chand et al. [73] demonstrated that the antitumor response to PARPi in PDA is largely controlled by the HuR-dependent stabilization of poly (ADP-ribose) glycohydrolase (PARG) [73]. The gene discussed is ELAVL1; the disease is Patent ductus arteriosus.